Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Preferred Stock Liabilities: 2015-2016

  • Voyager Therapeutics' Preferred Stock Liabilities rose 0.13% to $36.1 million in Q4 2016 from the same period last year, while for Dec 2016 it was $36.1 million, marking a year-over-year increase of 0.13%. This contributed to the annual value of $36.1 million for FY2016, which is 0.13% up from last year.
  • Voyager Therapeutics' Preferred Stock Liabilities amounted to $36.1 million in Q4 2016, which was up 0.13% from $36.1 million recorded in Q4 2015.
  • In the past 5 years, Voyager Therapeutics' Preferred Stock Liabilities registered a high of $89.0 million during Q3 2015, and its lowest value of $36.1 million during Q4 2015.
  • For the 2-year period, Voyager Therapeutics' Preferred Stock Liabilities averaged around $53.7 million, with its median value being $36.1 million (2016).
  • Data for Voyager Therapeutics' Preferred Stock Liabilities shows a peak YoY rose of 0.13% (in 2016) over the last 5 years.
  • Over the past 2 years, Voyager Therapeutics' Preferred Stock Liabilities (Quarterly) stood at $36.1 million in 2015, then climbed by 0.13% to $36.1 million in 2016.
  • Its Preferred Stock Liabilities was $36.1 million in Q4 2016, compared to $36.1 million in Q4 2015 and $89.0 million in Q3 2015.